ICPO Foundation >> Theranostics Centers

ICPO THERANOSTICS 
CENTERS OF EXCELLENCE

The ICPO Foundation supports a network of Theranostics Centers worldwide – particularly in low- and middle-income countries – to improve clinical practice, accelerate education, and drive innovation. In this respect the ICPO Theranostics Centers of Excellence accreditation forms the cornerstone of our global effort to increase equitable access to high-quality Theranostics care. By joining the ICPO network, Theranostics Centers benefit from an accreditation scheme aligned with international standards and shared values from the world‘s leading nuclear medicine societies.
LEARN MORE ABOUT THE ICPO CENTER SUPPORT

3-Level Accreditation Process:

#1

CLINICAL

Center of Excellence

  • Documentary review
  • ICPO Material and visibility

#2

COMPREHENSIVE

Center of Excellence

  • Live virtual review
  • Dedicated support from ICPO experts

#3

REFERENCE

Center of Excellence

  • On site audit
  • Recommendations towards scaling & translational research
Following international guidelines fron IAEA, SNMMI, EANM and ENETS

Benefits for ICPO Theranostics Centers of Excellence

1

Dedicated Support to improve Best Practices & Innovation in Theranostics

2

Exchange with Theranostics Experts Paired from the ICPO Network

3

Increase International and Regional Visibility to Grow Access and Referrals

HOW TO BECOME AN ICPO ACCREDITED CENTER

Join the worldwide network of ICPO Clinical Theranostics Centers of Excellence and get your center accredited! Through standardized processes, shared expertise, and certified education, ICPO will support your center to improve cancer patient outcomes and contribute locally to a global mission.
APPLY HERE

MAP OF ICPO
CENTERS NETWORK

This is the interactive map of Clinical Theranostics Centers of Excellence accredited by the ICPO Foundation. For direct contact with the respective Theranostics care teams, please use the ICPO Center Links.
VIEW COMPLETE LIST OF ICPO CENTERS

News

ICPO CENTERS TOOLS

The ICPO Centers Tools bring together practical resources to empower Theranostics centers worldwide.
Explore educational resources developed by ICPO and its partners, discover the AI-powered clinical trial finder and benefit from curated scientific publications. Such tools support your clinical practice, research and continuous knowledge growth. More tools to come.

RECOMMENDED PUBLICATIONS IN THERANOSTICS

This publications collection is designed to serve as a valuable reference for Theranostics centers worldwide, offering insights into the latest research, innovations, and clinical practices. Stay updated with cutting-edge developments in Theranostics and enhance your center‘s expertise.

The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.

Weber WA, Czernin J, Anderson CJ, et al. J Nucl Med. 2020 Dec; 61(Suppl 2):263S–272S
pubmed.ncbi.nlm.nih.gov/33293447/

Radiotheranostics: a roadmap for future development.

Herrmann K, Schwaiger M, Lewis JS, et al. Lancet Oncol. 2020 Mar;21(3):e146 - e156.
pubmed.ncbi.nlm.nih.gov/32135118/

Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright.

Czernin J., Calais J. Nucl Med Technol. 2020 Jun; 48(Suppl 1):82S–83S.
pubmed.ncbi.nlm.nih.gov/33293447/

Present and future of target therapies and theranostics: refining traditions and exploring new frontiers-highlights from annals of Nuclear Medicine 2021.

Pini C, Gelardi F, Sollini M. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3613–3621.
pubmed.ncbi.nlm.nih.gov/35870007/

Next generation radiotheranostics promoting precision medicine.

Pomykala KL, Hadaschik BA, Sartor O, et al. Ann Oncol. 2023 Jun;34(6):507–519.
pubmed.ncbi.nlm.nih.gov/36924989/

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Sartor O, de Bono J, Chi KN, et al. N Engl J Med. 2021 Sep 16;385(12):1091–1103.
pubmed.ncbi.nlm.nih.gov/34161051/

Combining External Beam Radiotherapy and 177Lu-PSMA-617: Bench to Bedside.

Arbuznikova D, Klotsotyra A, Uhlmann L, et al. Theranostics. 2024 Apr;14(6):2560–2572.
pubmed.ncbi.nlm.nih.gov/38646643/

Joint EANM/SNMMI Guideline for 177Lu-PSMA Radioligand Therapy.

Kratochwil C, Fendler WP, Eiber M, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830–2845.
pubmed.ncbi.nlm.nih.gov/37246997/

Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.

Lawhn-Heath C, Hope TA, Martinez J, et al. Lancet Oncol. 2022 Feb;23(2):e75–e87.
pubmed.ncbi.nlm.nih.gov/35114134/

Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy.

Graves SA, Hobbs RF. Semin Radiat Oncol. 2021 Jan;31(1):37–44.
pubmed.ncbi.nlm.nih.gov/33246635/

Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics center.

Herrmann K, Giovanella L, Santos A, et al. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2300–2309.
pubmed.ncbi.nlm.nih.gov/35403861/

First-in-Human Study: 177Lu-FAP-2286 in Diverse Adenocarcinomas.

Baum RP, Schuchardt C, Singh A, et al. J Nucl Med. 2022 Mar;63(3):415–423.
pubmed.ncbi.nlm.nih.gov/34168013/

Impact of Theranostics Tumor Board on Patient Management.

Prasad V, Kim H, Trikalinos N, et al. J Nucl Med. June 2024, 65 (suppl 2) 242589.
jnm.snmjournals.org/content/65/supplement_2/242589

Clinical Relevance of Post-Therapy SPECT/CT in Prostate Cancer.

Prasad V, Kim H, Michalski J, et al. J Nucl Med. June 2024, 65 (suppl 2) 242599
jnm.snmjournals.org/content/65/supplement_2/242599

Recent Advances and Challenges in Radiopharmaceutical Sciences in Oncology.

Lapi SE, Scott PJH, Windhorst AD, Baum RP, et al. Lancet Oncology or ScienceDirect.
sciencedirect.com/science/article/abs/pii/S1470204524000305

Efficacy and Safety of 225Ac-PSMA-617 in mCRPC.

Yadav MP, Ballal S, Sahoo RK, et al. Theranostics. 2020;10(20):9364–9377.
pubmed.ncbi.nlm.nih.gov/32802197/

Biodistribution and Comparison of 68Ga-FAPI and 18F-FDG PET/CT.

Ballal S, Yadav MP, Moon ES, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1915–1931.
pubmed.ncbi.nlm.nih.gov/33244617/

Production and regulatory issues for theranostics.

Giammarile F, Paez D, Zimmermann R, et al. Lancet Oncol. 2024 Jun;25(6):e260–e269.
pubmed.ncbi.nlm.nih.gov/38821100/

Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.

Scott AM, Zeglis BM, Lapi SE, et al. Lancet Oncol. 2024 Jun;25(6):e250–e259.
pubmed.ncbi.nlm.nih.gov/38821099/

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Hofman MS, Tran B, Feldman DR, et al. J Nucl Med. 2024 May;65(5):740–743.
pubmed.ncbi.nlm.nih.gov/38388517/

A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225-labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)

Morris MJ, Wong JYC, Nordquist L, et al. J Clin Oncol. 2024;42(16_suppl):5010.
doi.org/10.1200/JCO.2024.42.16_suppl.5010

Actinium-225 targeted alpha particle therapy for prostate cancer.

Bidkar AP, Zerefa L, Yadav S, et al. Theranostics. 2024 May;14(7):2969–2992.
pubmed.ncbi.nlm.nih.gov/38773983/

Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.

Semin Nucl Med. 2024 Jul;54(4):537–556.
pubmed.ncbi.nlm.nih.gov/39019653/

Guiding principles on the education and practice of theranostics.

Pascual TNB, Paez D, Iagaru A, et al. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2320–2331
pubmed.ncbi.nlm.nih.gov/38453729/

Theranostics and artificial intelligence: new frontiers in personalized medicine.

Belge Bilgin G, Bilgin C, Burkett BJ, et al. Theranostics. 2024 Mar;14(6):2367–2378.
pubmed.ncbi.nlm.nih.gov/38646652/

Immune Response to Molecular Radiotherapy with 177Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome.

Kluge A, Baum RP, Bitterlich N, et al. Cancer Biother Radiopharm. 2024 Sep;39(7):541–550.
pubmed.ncbi.nlm.nih.gov/38905126/

Theranostics: Timing is Everything.

Turner JH. Cancer Biother Radiopharm. 2024 Nov;39(9):611–618.
pubmed.ncbi.nlm.nih.gov/38757676/

Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.

Deroose C.M., Baum R.P., et al. J Neuroendocrinol. 2024 Dec 9:e13479.
pubmed.ncbi.nlm.nih.gov/39653582/

Total-Body PET/CT: Pros and Cons.

Hicks RJ, Ware RE, Callahan J Journal: Academic Radiology, 2024
sciencedirect.com/science/article/pii/S0001299824000655

The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases.

thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900651-2/fulltext

PSMA PET–Detected Disease Extent and Overall Survival in High-Risk Nonmetastatic Castration-Resistant Prostate Cancer: An International Multicenter Retrospective Study.

Weber M, Fendler WP, Kumar ASR, Calais J, Czernin J, et al. Journal: Eur Urol. 2024
doi.org/10.1016/j.eururo.2024.01.019

Baseline Nodal Status on 68Ga-PSMA-11 PET/CT in Intermediate- to High-Risk Prostate Cancer: Prognostic Value from the proPSMA Trial.

Hofman M, Kasivisvanathan V, Link E, Buteau J, Roberts MJ, et al. Journal:Eur Urol Oncol. 2024
euoncology.europeanurology.com/article/S2588-9311%2824%2900251-7/fulltext

Management of Patients with Advanced Prostate Cancer: 2024 APCCC Report.

Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, et al. Journal: Eur Urol. 2024
sciencedirect.com/science/article/pii/S0302283824026101

Advances and Challenges in Precision Imaging.

Hricak H, Mayerhoefer ME, Herrmann K, Lewis JS, Pomper MG, et al. Journal: Lancet Oncol. 2024
sciencedirect.com/science/article/pii/S1470204524003954

Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Advanced Meningioma: Initial Safety and Efficacy.

Amerein A, Maurer C, Kircher M, Gäble A, Krebold A, et al. Journal of Nuclear Medicine December 2024, 65 (12) 1911-1916
doi.org/10.2967/jnumed.124.268217

Expression Prevalence and Dynamics of GPCR Somatostatin Receptors 2 and 3 as Cancer Biomarkers Beyond NET: A Paired IHC Approach.

Oron-Herman M, Kirmayer D, Lupp A, et al. Sci Rep 13, 20857 (2023).
doi.org/10.1038/s41598-023-47877-0

Dotatate PET/CT and 225Ac-Dotatate Therapy for Somatostatin Receptor–Expressing Metastatic Breast Cancer.

Ulaner GA, VanderMolen LA, Li G, Ferreira D Journal: Radiology. 2024;312(1):e233408
doi.org/10.1148/radiol.233408

SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.

Hope TA, Calais J, Goenka AH, et al. J Nucl Med. 2025 Jan;66(1):26-33.
pubmed.ncbi.nlm.nih.gov/39572227/

First-in-human SPECT/CT imaging of [211At]PSMA-5: Targeted alpha therapy in refractory prostate cancer.

Hofman MS, Tran B, Watabe T, et al. Eur J Nucl Med Mol Imaging. 2024 Dec 17.
pubmed.ncbi.nlm.nih.gov/39688698/

Overall survival with [177Lu]Lu-PSMA-617 vs. cabazitaxel in mCRPC (TheraP trial – secondary outcomes).

Hofman MS, Emmett L, Sandhu S, et al. Lancet Oncol. 2024 Jan;25(1):99-107.
pubmed.ncbi.nlm.nih.gov/38043558/

First-in-human safety, imaging, and dosimetry of [68Ga]Ga-DPI-4452 in ccRCC.

Hofman MS, Tran B, Feldman DR, et al. J Nucl Med. 2024 Feb;65(5):740-743.
pubmed.ncbi.nlm.nih.gov/38388517/

LuTectomy: [177Lu] Lu-PSMA-617 prior to radical prostatectomy in high-risk localized prostate cancer.

Eapen RS, Buteau JP, Jackson P, et al. Eur Urol. 2024 Mar;85(3):217-226.
pubmed.ncbi.nlm.nih.gov/37891072/

[177Lu] Lu-PSMA-617 + Enzalutamide in mCRPC (ENZA-p trial).

Emmett L, Subramaniam S, Crumbaker M, et al. Lancet Oncol. 2024 May;25(5):563-571.
pubmed.ncbi.nlm.nih.gov/38621400/

PSMA PET-detected disease extent & OS in high-risk nonmetastatic CRPC: Multicenter retrospective study.

Weber M, Fendler WP, Ravi Kumar AS, et al. Eur Urol. 2024 Jun;85(6):511-516.
pubmed.ncbi.nlm.nih.gov/38490855/

UpFrontPSMA trial: Sequential [177Lu] Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC.

Azad AA, Bressel M, Tan H, et al. Lancet Oncol. 2024 Oct;25(10):1267-1276.
pubmed.ncbi.nlm.nih.gov/39293461/

Advanced Prostate Cancer Management: 2024 APCCC Consensus Report.

Gillessen S, Turco F, Davis ID, et al. Eur Urol. 2025 Feb;87(2):157-216.
pubmed.ncbi.nlm.nih.gov/39394013/

Radiotherapy and Theranostics: A Lancet Oncology Commission.

May Abdel-Wahab et al. Lancet Oncol. 2024 Nov;25(11):e545-e580.
pubmed.ncbi.nlm.nih.gov/39362232/

Baseline Nodal Status on ⁶⁸Ga-PSMA-11 PET/CT in Intermediate- to High-risk Prostate Cancer is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.

Michael S. Hofman et al. Eur Urol Oncol. Published online 2024 Nov 28.
pubmed.ncbi.nlm.nih.gov/39613566/

First Clinical Experience of ⁶⁸Ga-FAPI PET/CT in a Tertiary Cancer Center: Identifying Pearls and Pitfalls.

Akram Al-Ibraheem et al. Diagnostics (Basel). 2025 Jan 19;15(2):218.
pubmed.ncbi.nlm.nih.gov/39857102/

Overall Survival and Quality of Life with [¹⁷⁷Lu]Lu-PSMA-617 plus Enzalutamide versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer (ENZA-p Trial).

Louise Emmett et al. Lancet Oncol. 2025 Mar;26(3):291–299.
pubmed.ncbi.nlm.nih.gov/39956124/

Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from the Nuclear Medicine Global Initiative.

Akram Al-Ibraheem et al. J Nucl Med. Published online 2025 Mar 27.
pubmed.ncbi.nlm.nih.gov/40147850/

FDA Expands Pluvicto’s Metastatic Castration-resistant Prostate Cancer Indication.

News Article
ow.ly/cUxc50Vr0oK

Alpha Atlas: Mapping Global Production of α-Emitting Radionuclides for Targeted Alpha Therapy

Tosato M et al. Nucl Med Biol. 2025 Mar-Apr;142–143:108990.
pubmed.ncbi.nlm.nih.gov/39809026/

Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging – FAP-RADS Version 1.0

Novruzov E et al. J Nucl Med. Published online 2025 Jun 5.
pubmed.ncbi.nlm.nih.gov/40473461/

Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer

Speltri G et al. Mol Diagn Ther. 2025 Jul;29(4):453–463.
pubmed.ncbi.nlm.nih.gov/40474033/

Imaging Efficacy of [¹⁸F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study

Iagaru A et al. J Nucl Med. Published online 2025 Jun 5.
pubmed.ncbi.nlm.nih.gov/40473463/

Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data

Unterrainer LM et al. J Nucl Med. 2025 Jul 1;66(7):1054–1060.
pubmed.ncbi.nlm.nih.gov/40274370/

Multicycle Dosimetric Behavior and Dose–Effect Relationships in [¹⁷⁷Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Kayal G et al. J Nucl Med. 2025 Jun 2;66(6):900–908.
pubmed.ncbi.nlm.nih.gov/40274371/

[¹⁷⁷Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors – A Comprehensive Review

Al-Ibraheem A et al. Semin Nucl Med. Published online 2025 Jul 3.
pubmed.ncbi.nlm.nih.gov/40615277/

PET Imaging and Radionuclide Therapy in Neuroendocrine Prostate Cancer: A Systematic Review

Abdlkadir AS et al. Q J Nucl Med Mol Imaging. 2025 Jun;69(2):99–117.
pubmed.ncbi.nlm.nih.gov/40605655/

Clinical Utility of Post-Therapy SPECT/CT After the 1st Cycle of ¹⁷⁷Lu-PSMA-617 Therapy in Detecting Interim Disease Progression Compared to Pre-Therapy PSMA PET/CT

Parihar AS et al. J Nucl Med. 2025 Jun;66(Suppl 1):251407.
jnm.snmjournals.org/content/66/supplement_1/251407

Overall Survival of Prostate Cancer Patients Treated with ¹⁷⁷Lu-PSMA-617 (Pluvicto®) in a Multidisciplinary Setting – A Single Center Experience

Prasad V et al. J Nucl Med. 2025 Jun;66(Suppl 1):251559.
jnm.snmjournals.org/content/66/supplement_1/251559

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.

Emmett L et al. Lancet Oncol. 2025 Sep;26(9):1168-1177
pubmed.ncbi.nlm.nih.gov/40752515/

The Clinical Impact of FAPI PET Imaging: HCC, CCC, CUP & Peritoneal Carcinoma.

Novruzov E, Mamlins E, Mori Y, Cardinale J, Giesel FL. Semin Nucl Med. 2025 Sep;55(5):724-733.
pubmed.ncbi.nlm.nih.gov/40683830/

The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country.

Mogensen AW et al. Nucl Med. 2025 Aug 1;66(8):1217-1222.
pubmed.ncbi.nlm.nih.gov/40506242/

Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access

Akram Al-Ibraheem et al. Seminars in Nuclear Medicine Volume 55, Issue 6, November 2025, Pages 1032-1044
doi.org/10.1053/j.semnuclmed.2025.07.005

The molecular blueprint of targeted radionuclide therapy

Ken Herrmann et al. Nature Reviews Clinical Oncology volume 22, pages869–894 (2025)
nature.com/articles/s41571-025-01069-z

FAP-Targeted Radiopharmaceutical Therapy using 177Lu-, 90Y- and 225Ac-labeled 3BP-3940 in a Cohort of 88 Patients with 21 Different Advanced Malignancies

Richard p. Baum et al. Journal of Nuclear Medicine June 2025, 66 (supplement 1) 252205;
jnm.snmjournals.org/content/66/supplement_1/252205

Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

Louise Kostos et al. Lancet Oncology 2025 October 18
thelancet.com/journals/lanonc/article/PIIS1470-2045%2825%2900559-5/abstract
menuchevron-downarrow-upcross-circle